Keith Regnante is the Chief Financial Officer of City Therapeutics. Mr. Regnante is a seasoned CFO with more than 25 years of public biopharmaceutical company experience.

Prior to joining City, Mr. Regnante served as CFO of Keros Therapeutics, where he led the company’s finance organization during a time of significant growth and capital financing, including an IPO, two follow-on offerings, and a global licensing agreement with Takeda Pharmaceutical Company. Previously, Mr. Regnante served as CFO of Wave Life Sciences and held finance leadership roles of increasing responsibility at Shire Pharmaceuticals (subsequently acquired by Takeda Pharmaceutical Company) and Biogen, including senior positions in corporate finance and global research and development finance, as well as roles in investor relations and business development finance.

Mr. Regnante began his career as a consultant at the Boston Consulting Group and KPMG. He received an MBA from the MIT Sloan School of Management and a bachelor’s degree in Economics from Tufts University.